Advanced Accelerator Applications, a radiopharmaceutical diagnostics company developing its first therapeutic product, announced terms for its IPO on Monday.
The Saint Genis Pouilly, France-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Advanced Accelerator Applications would command a fully diluted market value of $617 million.
Advanced Accelerator Applications, which was founded in 2002 and booked $89 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol AAAP. Citi and Jefferies are the joint bookrunners on the deal. The expected pricing date is November 10, 2015.
